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Summary
Proteins in basement membrane (BM) are long-lived and accumu-
late chemical modifications during aging; advanced glycation
endproduct (AGE) formation is one such modification. The human
lens capsule is a BM secreted by lens epithelial cells. In this study,
we have investigated the effect of aging and cataracts on the AGE
levels in the human lens capsule and determined their role in the
epithelial-to-mesenchymal transition (EMT) of lens epithelial cells.
EMT occurs during posterior capsule opacification (PCO), also
known as secondary cataract formation.We found age-dependent
increases in several AGEs and significantly higher levels in
cataractous lens capsules than in normal lens capsules measured
by LC-MS/MS. The TGFb2-mediated upregulation of the mRNA
levels (by qPCR) of EMT-associated proteins was significantly
enhanced in cells cultured on AGE-modified BM and human lens
capsule compared with those on unmodified proteins. Such
responses were also observed for TGFb1. In the human capsular
bag model of PCO, the AGE content of the capsule proteins was
correlatedwith the synthesis of TGFb2-mediated a-smoothmuscle
actin (aSMA). Taken together, our data imply that AGEs in the lens
capsule promote the TGFb2-mediated fibrosis of lens epithelial
cells during PCO and suggest that AGEs in BMs could have a
broader role in aging and diabetes-associated fibrosis.
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Introduction
The human lens capsule is a BM secreted by lens epithelial cells and is
composed of interacting networks of laminin and type IV collagen in
addition to several heparin sulfate proteoglycans (Danysh & Duncan,
2009). The capsule encloses the lens, sequestering it from other ocular
tissue and protecting it from infections. It also provides vital epitopes for
the surface receptors of lens cells, which promote lens cell survival, cell
migration, and differentiation (Blakely et al., 2000; Tholozan et al.,
2007).
Because BM proteins, including proteins in the lens capsule, are long-
lived, these proteins accumulate post-synthetic modifications from
enzymatic amino acid cross-linking, lipid peroxidation, and glycation
during aging (Sell & Monnier, 1995). Glycation is the reaction of carbonyl
compounds, including glucose, ascorbate oxidation products, and
methylglyoxal, that forms a variety of structurally diverse stable adducts
in proteins; these adducts are collectively known as advanced glycation
endproducts or AGEs (Singh et al., 2001). Several studies have shown
the accumulation of AGEs in the aged BM of the kidneys, lungs, and lens
capsule (Bailey et al., 1993; Oldfield et al., 2001; Song et al., 2011).
During cataract surgery, a circular segment of the anterior lens
capsule is cut open in a procedure called anterior capsulorhexis
(Mohammadpour et al., 2012). The lens fiber mass is then emulsified
using a probe inserted through this opening and suctioned out in a
procedure commonly known as phacoemulsification. The inside lining of
the remaining capsule is ‘polished’ to remove anteriorly adhered
epithelial cells; next, an artificial intraocular lens is inserted in place of
the removed cataract. In most cases, this procedure is safe and initially
restores vision. However, in a significant number of patients, epithelial
cells that are stubbornly adhered to the remaining anterior capsule move
along the capsule to the posterior visual axis behind the intraocular lens
and undergo epithelial-to-mesenchymal transition (EMT), become
fibrotic, and cause wrinkling of the posterior capsule (Wormstone et al.,
2009). This process is known as posterior capsule opacification (PCO) or
secondary cataract formation. PCO impedes vision and requires YAG-
laser treatment to remove the fibrotic mass to clear the visual axis.
However, laser treatment could have unintended ill effects, albeit at a
low occurrence; these effects can include retinal detachment, macular
edema, corneal edema, and displacement of intraocular lens (Billotte &
Berdeaux, 2004). Thus, efforts are being made to inhibit PCO develop-
ment.
Many studies have shown that TGFb-mediated signaling through the
Smad pathway is essential for lens epithelial cell EMT (Dawes et al.,
2007; Eldred et al., 2011). These studies have proposed that TGFb is
released in response to injury to the lens during cataract surgery and
promotes PCO. The role of TGFb in PCO is supported by many studies in
which TGFb has been shown to induce the expression of a-smooth
muscle actin (aSMA), fibronectin, and collagen type I and III and reduce
the expression of vimentin, Snail1/2, and E-cadherin; these changes are
all hallmark features of the EMT (Lee et al., 2006; Eldred et al., 2011). In
addition, aberration in integrin-mediated cell anchoring has also been
implicated in lens epithelial cell EMT (Mamuya et al., 2014). Recent
studies have also shown a role for aldose reductase, MMP, microRNA,
and histone deacetylases in lens epithelial cell EMT (Yadav et al., 2009;
Wang et al., 2013; Korol et al., 2014; Xie et al., 2014).
Several studies have suggested a role for AGEs in EMT; kidney tubular
epithelial cell EMT and fibrosis, which occur in diabetic nephropathy, are
mediated through engagement of the receptor for AGEs (RAGE) with
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AGEs, followed by the synthesis of connective tissue growth factor and
can be inhibited by AGE inhibitors (Oldfield et al., 2001; Burns et al.,
2006; Sugimoto et al., 2007). The AGE–RAGE interaction also enhances
TGFb1 expression and induces fibrosis of the peritoneal membrane (De
Vriese et al., 2003). AGE-modified collagen promotes cardiac fibroblast
differentiation into myofibroblasts (Yuen et al., 2010), and AGE block-
ade reduces bleomycin-induced pulmonary fibrosis in rats (Chen et al.,
2009). Taken together, these observations support a role for AGEs in
fibrotic diseases.
The role of lens capsule AGEs in the EMT that occurs during PCO is
not known. Because cataract surgery is common in the elderly, we
hypothesized that age-associated accumulation of AGEs in aged
capsules could promote PCO. In this study, we investigated the effect
of age on the AGE levels in the lens capsule and then studied the effect
of AGE modification in the extracellular matrix on the TGFb-mediated
EMT in human lens epithelial (HLE) cells.
Results
AGE levels increase with age in both anterior and posterior
lens capsules
We measured 9 AGEs, of which four were exclusively lysine-derived,
three were exclusively arginine-derived, and two were cross-linking
modifications formed between lysine and arginine residues. All AGE
levels are expressed as pmol lmol1 leucine equivalent. In the posterior
capsule, AGEs accumulated progressively with age. Among the
lysine-derived AGEs, we measured pyrraline, N6-formyllysine (NFL),
N6-acetyllysine (NAL), and CML. CML was the dominant form (Fig. 1).
In young lenses (< 30 years), the levels were close to 5000 pmol, and the
levels increased to upwards of 10 000 pmol in aged capsules
(> 60 years) (Table S2). The second dominant AGE was NAL, which
was present at 1000 to 2000 pmol in young capsules and accumulated
to levels as high as 4800 pmol in aged capsules. Similarly, NFL and
pyrraline were present at ~800 to 1500 pmol, and ~2 to ~30 pmol,
respectively, in young capsules and reached ~3400 and ~125 pmol,
respectively, in aged capsules. Among the arginine modifications, N5-(5-
hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) was dominant.
This modification was present at approximately 3000 pmol in young
capsules and reached as high as 10 000 pmol in aged capsules. The N6-
carboxymethylarginine (CMA) levels were more or less steady
throughout aging at approximately 3000 pmol. However, the
N6-carboxyethylarginine (CEA) levels rose sharply with aging from
~2800 pmol in young capsules to ~6000 pmol in aged capsules. The
third category of AGEs was the lysine–arginine cross-linking structures.
We measured glucosepane, which was present at ~125 pmol in young
capsules and rose to ~500 pmol in aged capsules. Another lysine–
arginine cross-linking structure, 2-ammonio-6-({2-[(4-ammonio-5-oxido-
5-oxopentyl)-amino]-4-methyl-4,5-dihydro-1H-imidazol-5-ylidene}-
amino)-hexanoate (MODIC), was present in relatively small amounts; the
levels were approximately 5 pmol and 15 pmol in young and aged
capsules, respectively.
The levels of several AGEs in the anterior capsule were similar to those
in the posterior capsule (Fig. 1). For example, the CML, pyrraline, and
NAL levels were very similar to the levels in the posterior capsule.
However, the levels of NFL were slightly lower and ranged from
~800 pmol in young capsules to ~2000 pmol in aged capsules. Among
the arginine modifications, the MG-H1 and CMA levels were similar to
the levels in the posterior capsule, but the CEA levels were slightly lower
and ranged from ~1200 pmol in the young capsules to ~4800 pmol in
the aged capsules. The levels of the two lysine–arginine cross-linking
structures were very similar to the levels in the posterior capsule. Taken
together, these data show that all AGEs accumulated in the capsule with
aging and that the rates of accumulation with age were somewhat
similar in the anterior and posterior capsules.
We then compared the AGE levels in the posterior and anterior
capsules of young (< 30 years) and aged (> 60 years) lenses and found
that most AGEs are present at higher levels on both sides of the capsule
in aged lenses than in young lenses (Table S2). The greatest difference
between the two groups was observed for glucosepane, which was at
least 2.5-fold higher, both in the posterior and anterior sections of the
aged capsules than in the young capsules. Most other AGEs increased
anywhere from 1.5- to 2-fold in the aged capsules (except for pyrraline
and CMA in posterior capsules). These results further confirm the
accretion of AGEs in aged capsules.
AGE levels are higher in cataractous lens capsules than in
normal anterior lens capsules
We measured the AGE levels in the anterior capsules from cataractous
donor lenses (49–75 years), which were obtained during capsulorhexis.
The levels of CML ranged between ~3900 and ~10 000 pmol in normal
capsules and were significantly (P < 0.0005) increased to ~10 000 to
16 200 pmol in cataractous capsules (Fig. 2). A similar pattern of
increase was observed for NFL (P < 0.005) and pyrraline (P < 0.005). The
levels of NAL were more or less the same in the cataractous and normal
lens capsules. Among the arginine-derived AGEs, the CEA levels were
~2600 to 5800 pmol in normal capsules and were significantly
(P < 0.0005) higher and ranged from ~2400 to ~8200 pmol in the
cataractous lens capsules. The MG-H1 and CMA levels were similar
between the noncataractous and cataractous lens capsules. The lysine–
arginine cross-linking AGE, MODIC (P < 0.0005), was significantly
higher in cataractous lens capsules than in normal lens capsules. There
was a trend toward an increase, although not significant, in the other
lysine–arginine cross-linking glucosepane in cataractous capsules. The
total AGE content was significantly higher across the age range- and
age-matched groups in the cataractous lens capsules than in the normal
lens capsules (Fig. S1). Taken together, our data indicated that AGEs
accumulate in aging lens capsules and that AGEs are formed at higher
levels in the capsules of cataractous lenses than in the age-matched
normal lens capsules.
AGEs in glycated basement membrane extract (BME)
Using LC-MS/MS, we measured 5 AGEs in the AGE-modified BME. The
pyrraline levels significantly (P < 0.05) increased from ~30 pmol in
unmodified BME to 50 pmol lmol1 leucine equivalents in AGE-
modified BME (Fig. 3). The MG-H1 levels increased ~fivefold from
2000 pmol in the unmodified BME to 10 000 pmol in AGE-modified
BME (P < 0.0005). These levels were comparable to the AGE levels in the
human lens capsules; for example, the MG-H1 levels of ~10 000 pmol in
the aged human lens capsules were close to the ~9900 pmol in
the AGE-modified BME. Similarly, the CMA levels were threefold
higher in AGE-modified BME (P < 0.05). MODIC was twofold higher in
the AGE-modified BME than in unmodified BME (P < 0.05). We could
not detect CML in the AGE-modified BME because of matrix suppression
effects. Alternatively, we measured MG-H1 and CML by ELISAs using
specific monoclonal antibodies. Both AGEs were present at signifi-
cantly higher levels (P < 0.0005), which were at least threefold higher in
AGE-modified BME than in unmodified BME (Fig. 3).
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AGE modification of BME enhances the TGFb2-induced EMT
response in HLE cells
We next evaluated whether the AGE modification of BME altered the
TGFb2-induced EMT response in HLE cells. Numerous studies have
implicated the TGFb/Smad signaling pathway in PCO (Saika et al., 2004;
Wormstone et al., 2004). aSMA, MMP2, CTGF, integrin aV, integrin a5,
integrin b1, miR4279, and miR1469 have been shown to be upregulated
by TGFb2 during the EMT of HLE cells (Dawes et al., 2007; Wang et al.,
2013; Mamuya et al., 2014). Therefore, we measured the mRNA levels
Fig. 1 The AGE levels increase in the aging
lens capsule. The anterior/posterior portion
of the human lens capsules was digested by
proteolytic enzymes and analyzed by LC-
MS/MS for AGEs.
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Fig. 2 The levels of individual AGEs in
cataractous lenses (n = 9) are higher than
those in normal lenses (n = 13). The
anterior lens capsules from cataractous and
age-matched normal lenses were analyzed
for AGEs by LC-MS/MS.
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of these proteins by qPCR. The AGE-modified BME (without TGFb2
treatment) showed significant upregulations in the mRNA levels of
MMP2, miR4279, and miR1469, with minor statistically insignificant
increases in aSMA, CTGF, and integrin aV. However, the effect of AGEs
became more prominent in the presence of TGFb2. There was a sixfold
increase in the mRNA levels of aSMA in the TGFb2-treated cells
compared with that in the untreated control cells (Fig. 4). This response
was eightfold higher in the cells on the AGE-modified BME compared
Fig. 3 The AGE levels are higher in AGE-
modified BME. To determine whether our
glycating mixture was able to generate
AGEs in BME, the AGE-modified or
unmodified BME was subjected to LC-MS/
MS analyses for AGEs (A). The bars
represent mean  SD of three independent
experiments. To verify whether well-coated
and glycated BME in 96-well plates had
AGE, we measured CML and MG-H1 using
direct ELISAs (B).
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with cells on the unmodified BME. Similarly, the mRNA levels of CTGF,
integrin aV, MMP-2, miR1469, and miR4279 were significantly higher
(P < 0.0005) in the cells cultured on AGE-modified BME than in the cells
cultured on unmodified BME. Other known upregulated genes by TGFb2
in HLE cells, for example, Smad 4 and 7, the integrins a5 and b1,
TGFbR1, and fibronectin, were also significantly upregulated in the cells
cultured on the AGE-modified BME compared with the expression on
the unmodified BME (Table S4). Our results reveal that the mRNA levels
of these proteins were significantly upregulated in HLE cells upon
treatment with TGFb2 and that such upregulation was exaggerated in
cells on the AGE-modified BME.
In contrast to the above results, the mRNA levels of miR204, miR184,
TGFbR2, TGFbR3, and BMP4, which have been previously shown to be
downregulated by TGFb2 in HLE cells (Dawes et al., 2007; Wang et al.,
2013), were expectedly downregulated by the TGFb2 treatment (Fig. 4).
However, the mRNA levels of TGFbR2 (P < 0.0005) and BMP4 (P < 0.05)
were further reduced significantly in the cells on the AGE-modified BME
compared with those on the unmodified BME. There were no apparent
differences in the mRNA levels of miR204, miR184, and TGFbR2 in the
cells on the unmodified or AGE-modified BME, possibly because these
mRNA levels were already highly downregulated by TGFb2.
We further verified the effect of the AGE-modified BME on the
TGFb2-mediated upregulation of aSMA by immunofluorescence. The
cells cultured on the unmodified BME and not treated with 10 ng mL1
TGFb2 showed very little aSMA staining (Fig. S2A). However, the cells in
similar conditions but with TGFb2 treatment showed more aSMA
staining. Similar analyses on AGE-modified BME showed that there was
already higher aSMA staining in the cells on the AGE-modified BME than
in the cells on the unmodified BME; upon TGFb2 treatment, there was a
significant increase (P < 0.0005) in the aSMA staining. Western blot
experiments showed that cells cultured on AGE-modified BME and
TGFb2-treated had significantly higher levels of aSMA (P < 0.0005) and
fibronectin (P < 0.0005) than those cultured on unmodified BME
(Fig. S2B,C). Moreover, cells cultured on AGE-modified BME showed
an increase in Smad2 phosphorylation after 0.5 h of TGFb2 treatment.
This was accompanied by an increase in pSmad2 translocation to the
nucleus (Fig. S3), suggesting the promotion of TGFb2 signaling by AGEs.
To further verify that AGEs promoted the EMT response of TGFb2, we
used aminoguanidine (AG) to block AGE formation during glycation of
BME. While TGFb2 treatment of cells cultured on AGE-modified BME
resulted in significantly higher mRNA levels of aSMA (P < 0.0005) and
CTGF (P < 0.0005), inclusion of AG during glycation of BME significantly
(P < 0.0005) reduced that effect (Fig. S4). This confirms that AGEs in
BME promote TGFb2-mediated EMT of HLE cells.
AGE modification of the human lens capsule enhances the
TGFb2-induced EMT response in HLE cells
We determined the effect of AGE-modified human lens capsules on HLE
cells. One capsule from a pair of capsules from the same donor was AGE-
Fig. 4 AGE-modified BME enhances the TGFb2-induced EMT marker levels in HLE cells. Lens epithelial cells were cultured on AGE-modified or unmodified BME and were
treated with 10 ng mL1 TGFb2 for 24 h. The mRNA levels of the EMT markers were quantified by qPCR. The bars represent mean  SD of four independent experiments.
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modified, and the other was similarly incubated in the buffer without the
glycating mixture. HLE cells were cultured on these capsule preparations,
and when the cells propagated to make a confluent monolayer on the
capsule, TGFb2 was added and the cells were cultured for another 24 h.
The EMT responsewas analyzed using qPCR. In agreementwith our results
on AGE-modified BME, the HLE cells cultured on the AGE-modified
capsule showed significant (P < 0.0005) increases in the mRNA levels of
aSMA, CTGF, and miR4279 over those in cells grown on the unmodified
capsule (Fig. 5). Similarly, the MMP2 expression was significantly
(P < 0.05) elevated in the cells grown on AGE-modified capsules. Other
known upregulated genes by TGFb2 in HLE cells, for example, fibronectin,
integrin a5, and Smad 4 and 7, were also significantly upregulated in the
cells culturedon theAGE-modified capsule comparedwith theunmodified
capsule (Table S5). In contrast, the mRNA levels of miR204 were
significantly reduced (P < 0.05) in the cells grown on the AGE-modified
capsule compared with those in the cells grown on the unmodified
capsule. The mRNA levels of BMP4, miR184, and TGFbR3 were all slightly
but statistically insignificantly reduced in the cells grown on the AGE-
modified capsule than in the cells grownon the unmodified capsule. Taken
together, these results suggest that the AGE modification of the capsule
promotes the EMT response of lens epithelial cells to TGFb2.
Relationship between capsule AGEs and the TGFb2-mediated
EMT response of epithelial cells in the lens capsule
We sought to determine whether there was a relationship between the
AGE content of the lens capsule and the EMT response of lens epithelial
cells to TGFb2. For this purpose, we resorted to the human capsular bag
model. Capsules of donors of varying age (15–78 years old) were
isolated, maintained in culture, and treated with or without 10 ng mL1
TGFb2 for 2 days and then maintained in SF EMEM until end point (day
28). The AGE levels were measured in small portions of the capsule by
LC-MS/MS. The individual and total AGE levels in each capsule are
shown in Table S6. The aSMA levels were measured by immunostaining
and analysis using IMAGE PRO PREMIER software (Media Cybernetics,
Warrendale, PA, USA). Interestingly, the aSMA synthesis in response to
TGFb2 showed a weak correlation with the age of the capsule (Fig. 6).
More interestingly, the aSMA response to TGFb2 also correlated with the
total AGE content of each capsule. For example, the TGFb2-induced
aSMA synthesis was highest in the 77-year-old capsule, which also had
the highest AGE content. Conversely, the TGFb2-induced aSMA
synthesis was lowest in the 15-year-old capsule, which had the lowest
levels of AGEs.
Fig. 5 The mRNA levels of EMT markers are elevated in HLE cells cultured on AGE-modified human lens capsules. Human lens capsules were isolated from young donors,
and the adherent epithelial cells were removed. These capsules were then either modified using glycating mixture for 7 days at 37°C or kept as a control (unmodified). HLE
cells were cultured on these capsules and treated with 10 ng mL1 TGFb2 for 24 h, and the mRNA levels of the EMT-associated protein markers were measured using qPCR.
The bars represent mean  SD of three independent experiments.
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We then analyzed the relationship between individual capsule AGEs
with the TGFb2-mediated aSMA synthesis in HLE cells in capsular bags.
Among all the AGEs, NAL, NFL, and MODIC stood out as most
significantly related with P values of 0.003, 0.009, and 0.005, respec-
tively (Table 1). MG-H1 and CMA were also significantly related, but not
as highly as NAL, NFL, and MODIC.
Matrix protein AGE modification enhances the EMT response
to TGFb1 in HLE cells
Because TGFb1 is the main isoform of TGFb in nonocular tissues, we
determined whether TGFb1 had effects similar to those of TGFb2 on
AGE-modified BME. Our results indicated that the mRNA levels of the
major EMT proteins were increased by TGFb1 and that such an increase
was further amplified in the cells cultured on the AGE-modified BME
rather than on the unmodified BME (Fig. S5).
Discussion
The objectives of this study were to determine whether the age of the
lens capsule influences the TGFb2-mediated EMT response in lens
epithelial cells and whether the AGEs in capsular proteins had any role in
this EMT response.
Our observation of the accumulation of structurally different AGEs in
the aging capsule suggests that many divergent pathways of glycation
are operative in a persistent and chronic manner in human lens capsules.
While the accumulation of pyrraline, NAL, NFL, and glucosepane
suggests glucose-mediated glycation (Hayase et al., 1989; Glomb &
Monnier, 1995), the accumulation of MODIC, CEA, and MG-H1
suggests glycation by methylglyoxal (Ahmed et al., 2002). We would
like to note that NAL can also originate from the enzymatic acetylation
of lysine residues (Lin et al., 1998). Furthermore, the accumulation of
CML suggests that in addition to nonoxidative glycation, there is an
undercurrent of oxidation in lens capsule modification that (I) triggers
fragmentation of the Amadori product of glucose and lysine and (II)
triggers formation of glyoxal from glucose and ascorbate oxidation
(Glomb & Monnier, 1995).
The higher levels of AGEs in the cataractous lens capsules than in the
normal lens capsules are similar to the higher levels of AGEs in
cataractous lens proteins (Nagaraj et al., 2012) and could be caused by
the higher levels of AGE precursors and/or the acceleration of mecha-
nisms for synthesizing AGEs in cataractous lenses. The AGE formation in
tissue proteins is enhanced by transition metal ions, oxidative stress,
phosphate, and neighboring positively charged amino acids (Chace
et al., 1991; Breyer et al., 2012). Whether any of these factors
contributed to the higher level of capsule AGEs in cataractous lenses is
not known and needs further investigation.
Our present study had several novelties:
1 Our study showed that lens epithelial cells adhering to young capsules
respond feebly to TGFb2 and consequently synthesize lower levels of
aSMA, which is a definitive marker for EMT, than epithelial cells
adhering to agedcapsules.Childrenoftenpresent thepearl-type form
of PCO and have pronounced Soemmering’s ring, which in effect is
fiber cell differentiation. It could be that the reduced sensitivity to
TGFb2 in the young lens epithelial cells is linked to their ability to
regenerate fiber cells when provided with appropriate stimulus. If a
cell goes down the transdifferentiation route, it is following a
divergent path to fiber differentiation. AGEs may therefore facilitate
EMT and thus promote the fibrotic form of PCO. Therefore, AGE
content could be a key determinant in the extent and characteristic
PCO features/type an individual patient is likely to present.
2 Our study clearly showed that there is a direct relationship between
capsule AGEs and the response to TGFb2 in HLE cells adhering to
the capsule. How AGEs promote the TGFb2 response is not known,
but we can propose a few possibilities. AGEs could interact with
RAGE, a receptor of AGEs, and enhance the TGFb2 response. The
interaction between RAGE and AGEs has been implicated in fibrosis
in other tissues (Oldfield et al., 2001; Song et al., 2011). Another
possibility is that AGEs in the capsule could affect integrins, which
are major conduits between epithelial cells and the lens capsule and
promote the TGFb2-mediated EMT response. In fact, alterations in
integrins, especially aV, have been implicated in PCO (Mamuya
et al., 2014). It is possible that inhibition of the AGE–RAGE
interaction could prevent PCO. These possibilities are currently
being investigated in our laboratory.
3 AGEs in general are produced in greater amounts in diabetes
because of the underlying hyperglycemia. Several studies, including
our own, have provided strong evidence for such a phenomenon
(Brownlee et al., 1984; Nagaraj et al., 2012). Based on our finding
in this study that AGEs promote the TGFb2-mediated EMT response
in HLE cells, it can be speculated that the PCO rate could be higher
in individuals with diabetes than in individuals without diabetes.
Fig. 6 The TGFb2-mediated synthesis of aSMA increases with age and is
proportional to the AGE content. The human lens capsular bags from 15- to 77-
year-old donors were treated with or without 10 ng mL1 TGFb2 for 48 h and
then maintained for 28 days. The aSMA content was assessed using
immunofluorescence. A small portion of the capsule was cut out after the
treatment and analyzed by LC-MS/MS for AGEs. The AGE levels in each capsule are
shown in Table S6. The right Y-axis represents the ratio between the fluorescence
from aSMA after and before (SF) the TGFb2 treatment. Inset: Representative
images of lens epithelial cells on a 77-year-old donor capsule without and with
TGFb2 treatment. Scale bar = 100 lm.
Table 1 Relationship between individual capsule AGEs and aSMA expression by
HLE cells in capsular bags
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Thus, our study provides a mechanism for the higher rate of PCO in
individuals with diabetes.
4 In addition to PCO, fibrosis occurs in many other diseases. In fact,
fibrosis in tissues is a major factor for human mortality (McAnulty,
2007). Moreover, the rate of fibrosis increases with age (Calabresi
et al., 2007). On the basis of the results of this study, we can now
explain why this might be the case. It is now well established that
the AGE levels in proteins increase with age, especially long-lived
proteins such as those present in basement membranes (Verzijl
et al., 2000). It is therefore possible that accumulated AGEs
promote fibrosis in aged individuals and contribute to disease
pathogenesis. Our study could explain why the fibrosis rate is higher
in diabetes, for example, in the pathogenesis of diabetic nephropa-
thy (Burns et al., 2006). Furthermore, the similar effects of TGFb1
and TGFb2 on the AGE enhancement of EMT further suggests that
basement membrane AGEs could play a role in TGFb1-mediated
fibrosis, such as the cardiac and lung fibroses that occur in the
diseases of these organs (Yuen et al., 2010; Song et al., 2011).
5 PCO develops in approximately 20–30% of patients after cataract
surgery (Findl et al., 2010). It is possible that these patients have
higher levels of AGEs in their lens capsules than those who do not
develop PCO during the same time period. Future studies on the
AGE levels in the anterior capsule obtained during the capsulorhexis
procedure of cataract surgery might shed light on this possibility.
Furthermore, it might be possible to predict, based on the AGE
content in capsulorhexis specimens, the onset of PCO in patients
undergoing cataract surgery; this prediction could be used for
customized treatments of PCO. Our study showed that the NAL,
NFL, and MODIC contents in the capsular proteins are highly related
to the TGFb2-mediated EMT response in HLE cells. Thus, it might be
possible to use these AGEs in capsulorhexis specimens as markers to
prospectively predict PCO after cataract surgery.
In summary, our study provided a convincing link between AGEs in
the lens capsule and the EMT of HLE cells and could pave the way for
future treatment modalities for PCO. This study should also spur research
interest in the fibrosis associated with diseases of aging and diabetes.
Experimental procedures
Lens capsules
Normal human lens capsules were isolated from frozen donor lenses
obtained from the Heartland Lions Eye Bank, Springfield, MO. Anterior
capsules from cataractous lenses were collected from the capsulorhexis
procedure during cataract surgery at the University Hospitals Eye
Institute, Cleveland, OH, with the approval of the Institutional Review
Board. Donor eyes for the capsular bag model were obtained from the
East Anglian Eye Bank (Norwich, UK). The research was approved by the
UK National Ethics Committee (REC 04/Q0102/57) and followed the
tenets of the Declaration of Helsinki regarding the use of human
material.
Enzymatic digestion of lens capsules
The capsule was gently peeled away from the lens with the help of
tweezers and was cut to separate the anterior and posterior sections
with the aid of phase-contrast microscope (the presence of cells
indicated anterior section). The capsules were gently shaken in 0.85%
NaCl for 72 h to remove the residual fiber mass and adherent epithelial
cells and digested using collagenase and pronase E (Spiro, 1967). Briefly,
the specimens were suspended in 0.1 M Tris–acetate buffer, pH 7.4, in
the presence of 0.005 M calcium acetate. Collagenase was added on
three consecutive days at 0.70%, 0.35%, and 0.10% w/w of the
capsule and maintained in a shaker incubator at 37°C. At the end of
incubation, undigested material was removed by centrifugation, and the
pH was adjusted to 7.8 with 0.5 M Tris. Pronase E at 0.70% (day 1),
0.35% (day 2), and 0.10% w/w (day 3) was used for the subsequent
digestion of the capsule. A small crystal of thymol was added at the
beginning of the enzymatic digestion to prevent bacterial growth. After
digestion, the mixture was passed through a 3-kDa cutoff filter,
vacuum–concentrated, and stored at 86°C until LC-MS/MS analysis.
Before analysis, we measured the amino acid content in the digested
material using leucine as the standard, as previously described (Nagaraj
et al., 1991).
High performance liquid chromatography–mass
spectrometric (LC-MS/MS) quantitation of AGEs
The HPLC apparatus (Jasco, Groß-Umstadt, Germany) consisted of a
pump (PU-2080 Plus) with a degasser (LG-2080-02) and a quaternary
gradient mixer (LG-2080-04), a column oven (Jasco Jetstream II) and an
autosampler (AS-2057 Plus). Mass spectrometric detection was con-
ducted on a API 4000 QTrap LC-MS/MS system (Applied Biosystems/
MDS Sciex, Concord, ON, Canada) equipped with a turbo ion spray
source using electrospray ionization in positive mode: sprayer capillary
voltage of 2.5 kV, nebulizing gas flow of 70 mL min1, heating gas of
80 mL min1 at 650°C, and curtain gas of 30 mL min1. Chromato-
graphic separation of AGEs in the enzyme-digested capsule samples was
performed on a stainless steel column packed with RP-18 material
(KNAUER, 250 9 3.0 mm, Eurospher-100 C18A, 5 lm, Berlin, Ger-
many) using a flow rate of 0.7 mL min1. The mobile phase used was
water (solvent A) and methanol/water (7:3 (v/v), solvent B). To both
solvents (A and B), 1.2 mL L1 heptafluorobutyric acid was added.
Analysis was performed at a column temperature of 25°C using gradient
elution of 2% (0–9.7 min)–10% (16 min)–60% (32 min)–100% (33.5–
40.5 min) of solvent B. For mass spectrometric detection, the scheduled
multiple reaction monitoring (sMRM) mode was used and consisted of
collision-induced dissociation (CID) of the protonated molecules with
compound-specific orifice potentials and fragment-specific collision
energies (Table 2). The limits of detection (LOD) and quantitation
(LOQ) for all monitored compounds are given in Table S1. Quantitation
was based on the standard addition method. More precisely, increasing
concentrations of authentic reference compounds at factors of 0.5, 1, 2,
and 3 times the concentration of the analyte in the sample were added
to separate aliquots of the sample. The aliquots were analyzed, and a
regression of response vs. concentration was used to determine the
concentration of the analyte in the sample. Calibration with this method
resolves potential matrix interferences. The AGE LC-MS/MS method
showed coefficients of variation < 5%.
AGE modification of basement membrane extract (BME)
Cultrex BME is a soluble form of basement membrane purified from the
mouse Engelbreth-Holm–Swarm tumor (Trevigen, Gaithersburg, MD,
USA). The AGE modification of BME was carried out after coating plates
with BME (50 lg mL1). The plates were incubated at 37°C with a
glycating mixture, consisting of 2 mM ascorbate, 25 mM glucose, and
250 lM methylglyoxal, for 1 week at pH 7.4.
To determine whether the above glycation procedure led to AGE
formation, we measured two AGEs. We coated 96-well cell culture plate
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wells with 50 lL of BME (50 lg mL1) at 4°C overnight and performed
the AGE modification described above. The wells were washed three
times with PBST before blocking at room temperature for 2 h with
300 lL of 5% nonfat dry milk in PBST. The wells were washed again
three times with PBST and incubated with either a monoclonal antibody
for CML or a monoclonal antibody for methylglyoxal-derived MG-H1
(both diluted 1:1000 in PBST containing 5% nonfat dry milk, each 50 lL
per well) for 1 h at 37°C in a humidified chamber. The 39 PBST-washed
wells were then incubated with 50 lL per well horseradish peroxidase-
conjugated goat anti-mouse IgG (diluted 1:5000; Promega Corp.,
Madison, WI, USA) for 1 h at 37°C. The enzyme reaction was assessed
by the addition of 100 lL of 3,3,5,5-tetramethylbenzidine (Sigma-
Aldrich, St Louis, MO) followed by the addition of 50 lL of 2 N sulfuric
acid. The chromophore absorbance was measured at 450 nm against a
blank well that was coated with BME without AGE modification and
processed similarly. In addition, we measured the AGE content (by LC-
MS/MS) in BME suspension (50 lg mL1) glycated with the same
glycating mixture as above for 1 week at 37°C.
Quantitative Real-Time PCR
HLE cells (~100 000) were seeded on AGE-modified or unmodified BME
in 10-cm plates in 20% FBS-MEM and maintained for 2–3 days (to reach
70–75% confluence). The medium was gradually changed to serum-free
medium (10% FBS-MEM for 24 h and then SF for 24 h) before
treatment with 10 ng mL1 TGFb2 for 24 h. After this treatment, RNA
was extracted from the cells using the RNeasy Plus Mini Kit (Qiagen,
Valencia, CA, USA). The RNA was reverse transcribed to generate cDNA
using the QuantiTect Reverse Transcription Kit (Qiagen). qPCR analysis
was performed for the EMT-associated genes using a LightCycler 96 real-
time PCR system (Roche Life Sciences, Indianapolis, IN, USA). The primers
used are listed in Table S3.
AGE modification of human lens capsules
Human lens capsules from young donors (27–32 years) were gently
shaken in 0.85% NaCl for 72 h to remove the residual fiber mass and
adherent epithelial cells. The removal of epithelial cells was confirmed
using phase-contrast microscopy. The capsules that were devoid of cells
were AGE-modified for 7 days using the above described glycating
mixture at 37°C. The capsules were then pinned onto the culture dish
using 0.05-mm pins so that the posterior side faced up, and the dishes
were gently washed with PBS five times before HLE cells were seeded on
them. The cells were allowed to attach for 72 h. After this procedure,
the cells were deprived of serum and treated with 10 ng mL1 TGFb2
for 24 h at 37°C. RNA was isolated and cDNA generated as described
above. qPCR analysis was performed using the CFX Connect Real-time
PCR system (Bio-Rad Laboratories, Hercules, CA, USA).
Human capsular bag model
Following the removal of corneo-scleral disks for transplantation
purposes, donor eyes were obtained from the East Anglian Eye Bank
within 48 h of death. A simulated phacoemulsification cataract opera-
tion was performed on the donor eyes in a laminar flow hood as
previously described (Liu et al., 1996). Match-paired capsular bags were
maintained in EMEM supplemented with 50 lg mL1 gentamicin. One
preparation within a donor pair was exposed to 10 ng mL1 TGFb2
(Sigma-Aldrich) for the first 2 days of culture and then maintained in
nonsupplemented EMEM for the remaining culture period. The second
preparation was maintained in nonsupplemented EMEM for the entire
culture period. The medium was replaced every 2–4 days, and ongoing
observations of cell growth were performed using a Nikon phase-
contrast microscope (Nikon, Tokyo, Japan) and a digital camera (Nikon)
to capture images. At the experimental end point (day 28), the culture
medium was removed from the petri dishes, and the capsular bags were
fixed by the addition of 4% formaldehyde (Sigma-Aldrich).
Immunohistochemistry
Fixed capsular bag samples, treated as above, were rinsed three times
with PBS followed by three washes in a solution of 0.02% w/v BSA and
0.05% v/v IGEPAL (Sigma-Aldrich) in PBS. The preparations were
permeabilized with PBS containing 0.5% v/v Triton X-100 (Sigma-
Aldrich) for 30 min. Three additional washes with 0.02% w/v BSA and
0.05% v/v IGEPAL in PBS were performed before nonspecific binding
sites were blocked with normal goat serum (Sigma-Aldrich) diluted 1:50
in 1% w/v BSA in PBS for 1 h. Anti-alpha-smooth muscle actin (aSMA)
mouse monoclonal antibody (Sigma-Aldrich) was diluted 1:100 with 1%
w/v BSA in PBS and applied for 1 h at 37°C. Three washes with 0.02%
w/v BSA and 0.05% v/v IGEPAL in PBS were performed, and aSMA was
visualized using an Alexa Fluor 488-conjugated goat anti-mouse
secondary antibody (Invitrogen, Paisley, UK) diluted 1:100 with 1%
w/v BSA in PBS for 1 h at 37°C. The preparations were washed a final
Table 2 Mass spectrometric parameters for AGE quantitation
Retention time
Precursor ion Product ion 1† Product ion 2‡ Product ion 3‡
Min m z1 DP/V m z1 CE/eV CXP/V m z1 CE/eV CXP/V m z1 CE/eV CXP/V
CML 3.1 205.1 50.0 130.2 17.0 9.5 84.1 46.0 13.0 56.1 59.0 8.0
NFL 4.7 175.1 40.0 112.1 20.0 13.0 84.1 35.0 7.0 129.1 15.0 13.0
CMA 5.7 233.1 55.0 70.1 27.5 12.0 116.1 23.0 10.0 118.2 22.0 5.5
NAL 6.3 189.2 40.0 126.1 18.0 10.0 84.2 31.0 5.0 143.1 14.0 10.0
CEA 10.7 247.1 51.0 70.2 48.0 11.0 116.2 25.0 10.0 132.1 24.0 10.0
MG-H1 11.3 229.2 55.0 70.1 43.0 12.0 116.2 20.5 9.0 114.1 22.5 9.0
Glucosepane 23.5/25.4§ 429.3 15.0 384.5 41.0 19.0 269.2 55.0 20.0 339.2 55.0 20.0
Pyrraline 26.6 255.2 38.0 175.2 17.0 13.0 237.2 12.0 19.0 148.3 29.0 13.0
MODIC 27.3 357.3 25.0 312.2 35.0 7.0 267.3 45.0 15.0 197.4 45.0 14.0
†MRM transition used for quantitation (quantifier), ‡MRM transition used for confirmation (qualifier), and §two diastereomeric compounds of glucosepane are present in the
capsule.
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three times with 0.02% w/v BSA and 0.05% v/v IGEPAL in PBS, floated
onto glass microscope slides, and placed in hydromount mounting
medium (National Diagnostics, Hull, UK). Images were viewed using a
Zeiss epifluorescence microscope and ZEISS software (Axiovision). To
determine the level of aSMA, IMAGE PRO PREMIER software (Media
Cybernetics) was employed using a method adapted from Wormstone
et al. (2006). The aSMA level was established by measuring the mean
intensity level of all pixels within the fluorescent micrographs.
Statistics
The data are presented as mean  SD of the specific number of
experiments indicated in the figure legends. The data were analyzed
using STATVIEW 5.0.1 software (SAS Institute Inc., NC, USA). The statistical
significance was evaluated by ANOVA followed by Fisher’s protected least
significant difference test, and differences were considered significant at
P < 0.05.
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